These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 30770126)

  • 1. Impact of Optimal Medical Therapy at Discharge on One-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China.
    He X; Wang Y; Cong H; Lu C; Wu J
    Clin Ther; 2019 Mar; 41(3):456-465.e2. PubMed ID: 30770126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).
    Zeymer U; Berkenboom G; Coufal Z; Belger M; Sartral M; Norrbacka K; Bakhai A;
    Int J Cardiol; 2013 Dec; 170(2):239-45. PubMed ID: 24225199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study.
    Bi Y; Gao R; Patel A; Su S; Gao W; Hu D; Huang D; Kong L; Qi W; Wu Y; Yang Y; Turnbull F;
    Am Heart J; 2009 Mar; 157(3):509-516.e1. PubMed ID: 19249422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimal Medical Therapy in Patients with Malignancy Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome: a BleeMACS Sub-Study.
    Iannaccone M; D Ascenzo F; De Filippo O; Gagliardi M; Southern DA; Raposeiras-Roubín S; Abu-Assi E; Henriques JPS; Saucedo J; González-Juanatey JR; Wilton SB; Kikkert WJ; Nuñez-Gil I; Ariza-Sole A; Song X; Alexopoulos D; Liebetrau C; Kawaji T; Huczek Z; Nie SP; Fujii T; Correia L; Kawashiri MA; García-Acuña JM; Alfonso E; Terol B; Garay A; Zhang D; Chen Y; Xanthopoulou I; Osman N; Möllmann H; Shiomi H; Kowara M; Filipiak K; Wang X; Yan Y; Fan JY; Ikari Y; Nakahashi T; Sakata K; Yamagishi M; Moretti C; Gaita F; Kalpak O; Kedev S
    Am J Cardiovasc Drugs; 2017 Feb; 17(1):61-71. PubMed ID: 27738920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of Insufficient Optimal Medical Therapy after Acute Myocardial Infarction.
    Haraguchi Y; Sakakura K; Yamamoto K; Taniguchi Y; Tsukui T; Seguchi M; Wada H; Momomura SI; Fujita H
    Intern Med; 2020 Jun; 59(12):1489-1495. PubMed ID: 32188806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in optimal medical therapy at discharge and clinical outcomes in patients with acute coronary syndrome in Thailand.
    Wongsalap Y; Kengkla K; Poolpun D; Saokaew S
    J Cardiol; 2021 Jun; 77(6):669-676. PubMed ID: 33455848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.
    Yan AT; Yan RT; Tan M; Huynh T; Soghrati K; Brunner LJ; DeYoung P; Fitchett DH; Langer A; Goodman SG;
    Am Heart J; 2007 Dec; 154(6):1108-15. PubMed ID: 18035083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of evidence-based cardiac drug therapy on mortality in patients with acute coronary syndrome: Findings from the Gulf COAST registry.
    Al-Zakwani I; Zubaid M; Alsheikh-Ali AA; Almahmeed W; Rashed W
    Cardiovasc Ther; 2018 Dec; 36(6):e12463. PubMed ID: 30079461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
    Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW
    J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing prevention and guideline-concordant care in Montenegro.
    Knežević B; Musić L; Batrićević G; Bošković A; Bulatović N; Nenezić A; Vujović J; Kalezić M
    Int J Cardiol; 2016 Aug; 217 Suppl():S32-6. PubMed ID: 27381861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea.
    Lee J; Lee S
    Pharmacotherapy; 2018 Nov; 38(11):1095-1105. PubMed ID: 30225928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
    Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
    Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry.
    Cirillo P; Di Serafino L; Taglialatela V; Calabrò P; Antonucci E; Gresele P; Palareti G; Patti G; Pengo V; Pignatelli P; Marcucci R
    Angiology; 2020 Mar; 71(3):235-241. PubMed ID: 31867981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-Converting Enzyme Inhibitor-based Versus Angiotensin Receptor Blocker-based Optimal Medical Therapy After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
    Park S; Kim YG; Ann SH; Park HW; Suh J; Roh JH; Cho YR; Han S; Park GM
    J Cardiovasc Pharmacol; 2021 Jan; 77(1):61-68. PubMed ID: 33165139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in optimal medical therapy prescription and mortality after admission for acute coronary syndrome: a 9-year experience in a real-world setting.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2018 Apr; 4(2):102-110. PubMed ID: 29394340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.
    Olson WH; Ma YW; Crivera C; Schein J; Lefebvre P; Laliberté F; Dea K; Germain G; Lynch SM
    J Med Econ; 2015; 18(12):1074-84. PubMed ID: 26407193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between the use of 4 recommended drug categories and patient perceptions of health status following an ACS event.
    Erickson SV; Rangarajan K; Kline-Rogers EM; Smith DE; Eagle KA
    J Manag Care Pharm; 2009 Sep; 15(7):533-42. PubMed ID: 19739876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.